Form DEFA14A Lyell Immunopharma, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
|
Filed by the Registrant
|
☒ | |
|
|
Filed by a Party other than the Registrant
|
☐ | |
Check the appropriate box:
|
☐
|
| |
Preliminary Proxy Statement
|
|
☐
|
| |
Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
☐
|
| |
Definitive Proxy Statement
|
|
☒
|
| |
Definitive Additional Materials
|
|
☐
|
| |
Soliciting Material Pursuant to § 240.14a-12
|
|
LYELL IMMUNOPHARMA, INC.
|
|
(Name of Registrant as Specified In Its Charter)
|
|
|
|
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
|
Payment of Filing
Fee (Check all boxes that apply):
|
☒
|
| |
No fee required
|
|
☐
|
| |
Fee paid previously with preliminary materials
|
|
☐
|
| |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sofy.ai Launches AI Test Agents for Microsoft Dynamics 365, Ending the Era of Broken Scripts and Manual QA Sprints
- Santa Barbara Foundation and California Lutheran University Center for Nonprofit Leadership Host PR Workshop Led by Marketing Maven CEO Lindsey Carnett
- Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar Medicines
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
